English

Meet Our Leadership Team


HAI YAN, PH.D.
President and CEO, Co-founder
Hai Yan is a recognized expert in the discovery and early development of monoclonal antibodies and other protein therapeutics for cell surface receptors implicated in human metabolic diseases. Hai Yan co-founded REMD Biotherapeutics in 2011 to advance the clinical development of AMG477, in-licensed as REMD-477Dr. Yan began his biotechnology career at Amgen in 1994 as research scientist in the Metabolic Disorders therapeutic area. In 2001, he accepted an appointment to Amgen Protein Sciences and developed an innovative monoclonal antibody platform for targeting GPCR signaling and cellular trafficking. His accomplishments at Amgen include the isolation of AMG477, the first therapeutic monoclonal antibody designed to inhibit glucagon receptor signaling and biological for the potential treatment of diabetic patients. He served as AMG477 project leader from its conception to early clinical development. His success at Amgen was recognized with numerous promotions, including that of Scientific Director. Dr. Yan graduated with a B.S. in Biochemistry, from Nanjing University in China in 1982. He obtained his Ph.D. from Cornell University Medical College in 1991 and performed his postdoctoral research with Joseph Schlessinger at New York University School of Medicine. Hai Yan is the key inventor and co-inventor for more than a dozen patents. He has authored more than thirty peer-reviewed scientific publications in cell signaling and metabolic disorders.  

TOM BOONE, M.S.
Chief Scientific Officer, Co-founder
Tom Boone has more than 28 years of accomplishments in the discovery and development of protein therapeutics. Prior to helping found REMD Biotherapeutics, Tom worked at Amgen and served in positions of increasing responsibility in growing Amgen Protein Sciences to an organization of over 300 researchers across five different sites while maintaining a long tradition of industry excellence. His career at Amgen began in 1981 with the isolation and cDNA cloning of novel cytokines and growth factors including G-CSF. Tom Boone’s responsibilities grew from Scientist to Director and he developed proprietary processes used to produce recombinant G-CSF and other therapeutic candidates for clinical applications. His continuing success led to leadership of all research protein technologies, and the evolution of Protein Sciences as an independent organization. Tom Boone was the first Vice President of Amgen Protein Science and his teams were responsible for the majority of the current Amgen product portfolio and late stage clinical programs. Tom was the inventor and a lead scientist in the development of Nplate®, a treatment of thrombocytopenia. His critical role in the discovery and process development of G-CSF (Neupogen) is widely recognized. Tom Boone’s expertise in protein engineering, production, purification and process development are in high demand. In addition to his responsibilities at REMD, he serves as a consultant or scientific advisor to more than 10 different companies and investment group.

DUNG "ZUNG" THAI, M.D., PH.D.
Chief Medical Officer
Zung has been Chief Medical Officer at REMD Biotherapeutics since June 2016. Prior to REMD, he held leadership roles at small and large companies including Atara, Arresto, Anza Biotherapeutics, and Gilead Sciences where he led the development of protein therapeutics in metabolism, oncology, infectious diseases and fibrotic diseases. He began his industry career at Amgen where he worked in early clinical development and metabolic disorder and initiated the first in human study of REMD-477. Zung earned an A.B. from Cornell University and his M.D. and Ph.D. in pharmacology from the University of Pittsburgh School of Medicine. He was a fellow and clinical instructor in the department of clinical pharmacology at University of California, San Francisco. Zung was a post-doctoral fellow at the University of California, Berkeley and Carnegie Mellon University. He is Board Certified in Internal Medicine.

FRANK J. CALZONE, PH.D.
Vice President, Discovery Research
Frank J. Calzone Ph.D. has over 22 years of experience in the isolation and preclinical development of protein therapeutics for cancer and other diseases. He recently was appointed as Vice President of Discovery Research for REMD Biotherapeutics. He is also a member of the UCLA Translational Oncology Research Laboratory (TORL) and his research specialties are tumor genomics and drug discovery. He joined Amgen as a research scientist in 1993 to identify novel growth factors and cytokines using genomics and transgenic mice. He is an inventor on the Amgen patent describing the isolation and characterization of osteoprotegerin which initiated the development of Prolia/Xgeva. In 2000, his research shifted to antibody therapeutics targeting growth factor and cytokine receptors in cancer. He led the team that generated Ganitumab, an inhibitory IGF1R antibody, and served as scientific lead as it advanced clinically. He was a member of the Amgen Ventures SAB, and departed the company as a Scientific Executive Director in 2012. Frank J. Calzone has a long history of public service in breast cancer research and advocacy. He has been a scientific advisor to the Artemis Project of the National Breast Cancer Coalition from the beginning of the program in 2010. He serves on the DOD-CDMRP-BCRP integration panel (2007-present) which has overseen the investment of over 3 billion dollars in breast cancer research. Frank J. Calzone received a Ph.D. in Molecular, Cellular and Developmental Biology from the University of Rochester. He performed his postdoctoral research in developmental biology at Caltech. He was an Assistant Professor (tenure track) at the University of California, Irvine in Developmental and Cell Biology (1989-1993). 


ZHIQING (JIM) SHI, M.D., PH.D.
Consultant, Former CMO of REMD
Zhiqing Shi joined REMD Biotherapeutics in 2013 to lead the clinical development of REMD477 for diabetes and other metabolic disorders. Prior to joining the company, Zhiqing Shi served as Medical Director at Amphastar Pharmaceuticals
(2005-2010) and later in the same capacity at the Genzyme Corporation (2011-2012). His administrative and managerial experiences at these companies included directing the teams responsible for IND enabling preclinical research, clinical study design, pharmacovigilance and clinical trial safety. Zhiqing Shi’s biotechnology career also includes nine year (1996-2009) with Amgen where he was advanced to the level of principal scientist in preclinical research developing obesity and diabetes therapeutics. Zhiqing Shi was trained (M.D./Surgical Residency) at Shanghai No. 2 Medical University in 1975 and practiced general surgery at the university's teaching hospital. He obtained a Ph.D. in Experimental Medicine at Canada's McGill University in 1986. His academic experience includes an appointment as an Assistant Professor at the University of Toronto in Physiology and Endocrinology (1993-1996). Zhiqing Shi has authored and co-authored more than 40 peer-reviewed scientific publications, and published numerous abstracts at scientific conferences.

JINGANG WANG, EMBA
Distinguished Advisor
Jingang Wang serves as the CEO of the Chinese subsidiary of REMD, COSCI-REMD. Jingang Wang is an expert with more than 25 years of experience in the regulatory processes and business practices required for drug development and commercialization in China. He has been a senior executive at number of pharmaceutical enterprises. He has played a leading role in the development and registration of more than 50 generic drugs in China. Jingang Wang is also the founder of COSCI Med-Tech specializing the in innovative slow-release technology and products. At the 20th Anniversary of the Zhongguancun Science and Technology Zone, he won the Outstanding Contributor Award and was one of the fifty awardees of the 2012 China Commercial Innovation Awards. As an inventor, Jingang has already secured 72 patents though the China National Patents Bureau.